Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

March 14, 2023

Raajit K. Rampal, MD, PhD, discusses how the role of JAK inhibitors will continue to evolve in the treatment of patients with myelofibrosis.

March 11, 2023

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

March 09, 2023

Pallawi Torka, MD, discusses the BTK inhibitors available for treatment of patients with relapsed/refractory mantle cell lymphoma.

March 08, 2023

Pallawi Torka, MD, discusses the clinical implications of the FDA approval of pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma.

March 06, 2023

Sergio A. Giralt, MD, discusses the rationale for investigating idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

March 06, 2023

Micheal Foote, MD, discusses the quest to determine optimal sequencing of current therapeutics in the third-line setting and beyond for metastatic colorectal cancer.

March 03, 2023

The advent of antibody-drug conjugates has placed a renewed focus on the lesser thought of HER2 classifications of IHC 1+ and 0.

March 02, 2023

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

March 02, 2023

Jonathan E. Rosenberg, MD, discusses key safety and efficacy data from the EV-103 trial supporting supplemental biologics license applications seeking FDA approval of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer.

February 27, 2023

Sergio A. Giralt, MD, discusses the investigation of idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

February 26, 2023

Lenvatinib in combination with pembrolizumab led to deep and durable tumor responses in patients with previously treated advanced endometrial carcinoma.

February 24, 2023

James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.

February 23, 2023

James Harding, MD, discusses key trials contributing to the evolution of frontline chemoimmunotherapy approaches in advanced biliary tract cancer.

February 20, 2023

Tiffany A. Traina, MD, discusses the significance of the FDA approval of sacituzumab govitecan for patients with metastatic hormone receptor-positive, HER2-negative breast cancer and expanded on the data from TROPiCS-02 that supported the approval.

February 17, 2023

Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.

February 13, 2023

James Harding, MD, highlighted current and emerging areas of research in biliary tract cancer, including key contributions from TOPAZ-1 and the phase 3 SWOG 1815 trial, the development of immunotherapy and chemotherapy combinations, and continued efforts to utilize personalized medicine in clinical practice.

February 02, 2023

For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.

January 25, 2023

Sergio A. Giralt, MD, discusses long-term outcomes with hematopoietic stem cell transplant in multiple myeloma

January 22, 2023

IK-175 was found to be well tolerated in patients with advanced solid tumors and to elicit responses in those with urothelial cancer when used alone or in combination with nivolumab, according to initial data from an ongoing phase 1a/b study.

January 21, 2023

Treatment with or without bevacizumab added to atezolizumab plus cisplatin/gemcitabine demonstrated a modest clinical benefit for patients with advanced biliary tract cancer.